We hope you've had a chance to review the press release we issued after market close in the U.S. today, announcing the positive top-line results of the Phase III ABTECT Maintenance trial. Joining me ...

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt ...

While lifestyle alterations have been previously recommended to control potassium levels for some patients with hyperkalemia, ...

You’ve followed your ulcerative colitis (UC) treatment plan to a T, and yet you’re still experiencing symptoms that won’t let up — or even seem to be taking a turn for the worse. There’s an ...

Older adults hospitalized with acute severe ulcerative colitis (ASUC) face substantially higher mortality rates, and current guidelines do not provide specific recommendations for this population. In ...

Ulcerative colitis (UC) is a lifelong condition. That means you may try a lot of different treatments — and know how frustrating it can be when they don’t help. The nature of UC is “flare and ...

T he goal of ulcerative colitis (UC) treatment is twofold: to heal the inflamed mucosal lining of the gut and to eliminate symptoms such as cramping and pain (usually once the inflammation subsides).

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

Eli Lilly said federal regulators have approved of a single-injection, once-monthly maintenance regimen in the U.S. for its ulcerative colitis treatment Omvoh. The pharmaceutical company said Monday ...

Share on Pinterest Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years, ...